The recently discovered selective nonsteroidal progesterone receptor (PR) antagonist 4-[3-cyclopropyl-1-(methylsulfonylmethyl)-5-methyl-1H-pyrazol-4-yl]oxy-2,6-dimethylbenzonitrile (PF-02413873) was characterized in metabolism studies in vitro, in preclinical pharmacokinetics in rat and dog, and in an initial pharmacokinetic study in human volunteers. Clearance (CL) of PF-02413873 was found to be high in rat (84 ml ⅐ min ؊1 ⅐ kg
Introduction
Endometriosis and uterine fibroids are common gynecological conditions that affect approximately 20 to 40% of women. These conditions are characterized by chronic pelvic pain, cyclical menstrual pain, excessive menstrual blood loss, and infertility. The most widely prescribed medical therapies for the treatment of endometriosis are gonadotropin releasing hormone analogs and the progestin medroxyprogesterone acetate (Olive, 2003) . Gonadotropin releasing hormone analogs and progestins are only for short-term use (6 months), because they result in bone mineral density loss as well as other side effects secondary to hypoestrogenism. A body of preclinical and clinical data suggests the potential utility of selective progesterone receptor (PR) antagonists, acting as functional estrogen antagonists, in the treatment of endometriosis and uterine fibroids (Grow et al., 1996; Kettel et al., 1996 Kettel et al., , 1998 Baird et al., 2003; Fiscella et al., 2006) . A selective PR antagonist would be expected to maintain estrogen at mid follicular levels, hence avoiding the systemic effects of hypoestrogenism.
A selective nonsteroidal PR antagonist, 4-[3-cyclopropyl-1-(methylsulfonylmethyl)-5-methyl-1H-pyrazol-4-yl]oxy-2,6-dimethylbenzonitrile (PF-02413873), was recently identified (Gibson et al., 2009) . Preclinical pharmacological and toxicological characterization of PF-02413873 suggested that systemic exposure levels in human that are likely to be required to elicit the desired functional estrogen antagonism could do so with an acceptable safety margin. Therefore, its preclinical pharmacokinetic (PK) properties were investigated to assess the likelihood that its PK in human would support its progression as a potential therapeutic agent. The accurate prediction of PK in human can be a significant challenge to drug discovery scientists, and a number of approaches have been used with varying degrees of success (Beaumont and Smith, 2009) . PK prediction methods have been described and compared in several retrospective analyses of groups of compounds (Obach et al., 1997; Ito and Houston, 2005; Jones et al., 2006a; Hosea et al., 2009 ), but there have been few examples reported that show a PK prediction strategy used in practice before initial first-in-human (FIH) clinical studies (Allan et al., 2008; Yamazaki et al., 2011) . The prospective approach used in the present article for PF-02413873 was to integrate the knowledge of its in vitro properties, including metabolic turnover and routes, with preclinical PK to determine likelihood of appropriate PK in human, by applying PK prediction methods and taking into account the weight of evidence presented in the literature. PK predictions often focus on parameters such as clearance (CL) and half-life (t 1/2 ) because these are determinants of dose and duration of action. However, it can also be of value to predict PK concentration versus time profiles (Allan et al., 2008) and the potential for food intake to influence absorption, particularly where drug candidates possess high lipophilicity and consequent low solubility. The latter point is especially relevant to PF-02413873 because its neutral and lipophilic nature was a requirement for its PR binding affinity.
This article describes the preclinical data obtained in in vitro and in vivo systems, the human PK prediction methods used, and the human PK of PF-02413873 subsequently determined in a FIH clinical study. Based on preclinical data, simulations of PK profiles were performed using physiologically based pharmacokinetic (PBPK) modeling as implemented in GastroPlus software (Simulations Plus Inc., Lancaster, CA), which also enabled the potential for food effects after oral dosing to be examined. This is the first reported study of human PK of a nonsteroidal PR antagonist. It additionally serves as a case example of the assessment of PK prediction, whereby the accuracy of PK prediction methods used for PF-02413873 may be viewed in the context of retrospective assessment of published PK prediction methods over ranges of compounds.
Materials and Methods
Dulbecco's phosphate-buffered saline (PBS) without CaCl 2 and MgCl 2 (PBS) was purchased from Sigma-Aldrich (St. Louis, MO). Spectra/Por dialysis membranes (120 ϫ 22 mm, molecular weight cutoff 12-14 kDa) were purchased from Spectrum Laboratories Inc. (Rancho Dominguez, CA). MF3 (2 mM ammonium acetate in 10% methanol, 90% water containing 0.027% formic acid) and MF4 (2 mM ammonium acetate in 90% methanol, 10% water containing 0.027% formic acid) were purchased from Romil (Cambridge, UK). PF-02413873 was synthesized in the Chemistry Department, Sandwich Laboratories, Pfizer Global Research and Development (Sandwich, UK) and was Ͼ95% pure. 4-[3,5-Dicyclopropyl-1-(methylsulfonylmethyl)-1H-pyrazol-4-yl]oxy-2,6-dimethylbenzonitrile) (PF-02339955) and 4-[3,5-dicyclopropyl-1-(N-methyl-acetamide)-1H-pyrazol-4-yl]oxy-2,6-dimethylbenzonitrile (PF-02327888) were analogs of PF-02413873 that were used as internal standards in bioanalytical assays and were also synthesized at Pfizer Global Research and Development. logD 7.4 . logD 7.4 was measured by a fully automated shake flask method, performed on a Hamilton Microlab STAR (Hamilton Robotics, Inc., Reno, NV), that determined the partition of PF-02413873 between octanol and phosphate buffer, pH 7.4 (Stopher and McClean 1990) .
Caco-2 Transcellular Flux. The transcellular flux of PF-02413873 across Caco-2 cell monolayers was determined in both apical-to-basolateral and basolateral-to-apical directions using an established method (Walker et al., 2005) .
Solubility in Simulated Intestinal Fluids. Simulated intestinal fluids representing the fasted (FaSSIF) and fed (FeSSIF) states were prepared according to published recipes (Klein et al., 2005) . FaSSIF medium was supplemented with 3 mM sodium taurocholate and 1 mM lecithin, pH 6.5, and FeSSIF was supplemented with 15 mM sodium taurocholate and 9 mM lecithin, pH 6.5. To assess solubility, an excess of PF-02413873 was shaken in medium for 24 h at 37°C, and undissolved material was separated by centrifugation at 16,000g for 5 min. Medium concentration of PF-02413873 was determined by a highperformance liquid chromatography (HPLC) method.
Plasma Protein Binding. Plasma protein binding of PF-02413873 was determined at two concentrations of PF-02413873 in rat (1.5 and 15 g/ml), dog (1.0 and 10 g/ml), and human (0.1 and 1.0 g/ml) by equilibrium dialysis. In each species, pooled plasma was obtained from at least five donor subjects with plasma from males and females pooled separately. Equilibrium dialysis was performed using a 96-well device in which dialysis membranes (12-14 kDa cutoff) were incorporated that had been soaked in PBS for 1 h before use. Plasma samples (150 l) were dialyzed against an equal volume of PBS for 4 h at 37°C in an atmosphere of 5% CO 2 in the device that had been sealed with a breathable membrane. At the end of the incubation, samples of plasma and buffer were removed and stored at Ϫ80°C until analysis. Samples were matrix matched with blank reagents before analysis (i.e., 25 l of blank PBS was added to 25 l of plasma samples and vice versa). Protein precipitation was performed by addition of 200 l of methanol containing 100 ng/ml internal standard (PF-02339955) followed by centrifugation at 2000g at 6°C for 15 min. Samples of supernatant (150 l) were dried under a stream of nitrogen at 40°C, and the residues were reconstituted with 150 l of water/ methanol (1:1, v/v). After vortex mixing, samples were analyzed on a SCIEX API 4000 (AB Sciex Instruments, Foster City, CA) LC-MS/MS turbo ion spray system operating in positive ion mode under multiple reaction monitoring. The elution mobile phase was 45% 10 mM ammonium formate, pH 3.5, 55% acetonitrile delivered at 1 ml/min through a Zorbax SB column (C8 3.5 m, 75 ϫ 4.6 mm; MacMod Analytical, Inc., Chadds Ford, PA). A collision energy of 25 eV was used, and transitions of 360.28 to 280.20 and 386.16 to 306.16 were monitored for PF-02413873 and internal standard, respectively. The unbound fraction (Fu) of PF-02413873 was calculated by dividing the concentration in buffer by the concentration in plasma.
Blood Partitioning. The blood/plasma ratio of PF-02413873 was determined after incubation of PF-02413873 (1 g/ml) in rat, dog, and human blood for 3 h. After incubation, 50-l aliquots were removed and the remaining blood was centrifuged at 2000g for 10 min, after which 50-l aliquots of plasma were removed. Concentrations of PF-02413873 in whole blood and plasma were determined using the LC-MS/MS method described under PF-02413873 Analysis in Rat and Dog Plasma Samples. Separate calibration lines were determined using blank blood and plasma containing known added amounts of PF-02413873.
Metabolic Turnover in In Vitro Systems. The in vitro stability of PF-02413873 was studied in microsomes (BD Gentest, San Jose, CA) and cryopreserved hepatocytes (InVitro Technologies, Baltimore, MD) from rat, dog, and human liver and in human recombinant cytochrome (P450) isozymes (CYP1A2, 2C9, 2C19, 2D6, and 3A4; PanVera, Madison, WI). All incubations were performed at a concentration of 1 M PF-02413873. Liver microsome preparations were diluted to yield 0.5 M P450, and recombinant P450 isozymes were used at 0.1 M. Incubations (1.3 ml) contained 50 mM KPO 4 buffer (pH 7.4) and 1 mM MgCl 2 and were supplemented with a reducing equivalent regenerating system (isocitrate/isocitrate dehydrogenase). The assay cocktail was incubated at 37°C for 15 min before the addition of NADP ϩ (1 mM) to initiate reactions. Samples (100 l) were removed at time intervals up to 60 min after addition of NADP ϩ , and the reaction was quenched by addition of each aliquot to 200 l of acetonitrile containing fluconazole (1 M) as an internal standard. Cryopreserved rat, dog, and human hepatocytes were defrosted and washed according to the supplier's instructions. Incubations were carried out at a concentration of 1 M PF-02413873 with 0.5 ϫ 10 6 viable hepatocytes/ml in 50 l Williams E medium. Incubations were carried out for 3 h at 37°C in a CO 2 incubator, and reactions were terminated at time intervals of 3, 5, 10, 15, 30, 45 , and 60 min with 200 l of acetonitrile containing fluconazole (1 M) as an internal standard.
Samples (80 l) from microsomal and hepatocyte incubations were analyzed by LC-MS/MS using a Sciex API2000 mass spectrometer (PerkinElmerSciex Instruments). The API2000 was operated in positive ion mode using the turbo ion spray interface, and data were acquired in the multiple reaction monitoring (MRM) mode using argon as the collision gas. Chromatography was performed using a 2.1-mm C18 Opti-lynx special column with a pore diameter of 40 m (Optimize Technologies Inc., Oregon City, OR) and mobile phases A (2 mM ammonium acetate, pH 3, in 90% water, 10% methanol) and B (2 mM ammonium acetate, pH 3, in 10% water, 90% methanol). A step gradient of 0 to 10 s 100% A, 11 to 78 s 100% B, and 79 to 116 s 100% A was used with a flow rate of 1 ml/min. Flow was split (1:5) postcolumn before entering the mass spectrometer. Ratios of peak areas of PF-02413873 to internal standard were calculated, and the natural logarithm of peak area ratio was plotted against time. The apparent first-order rate constant taken from the slopes of the plots were used to calculate apparent intrinsic clearance (CL int,app ) and normalized per milligram of microsomal protein or per 10 6 hepatocytes.
Microsomal Binding. A human liver microsomal incubation was prepared as described above, but without addition of NADP ϩ , and left at room temperature overnight to inactivate metabolizing enzymes. PF-02413873 was added to the mixture to a final concentration of 1 M, and 220 l was used for equilibrium dialysis against blank buffer mix in a rapid equilibrium device (Waters et al., 2008) . After incubation at 37°C for 4 h, samples of microsomal incubation (15 l) and buffer (45 l) were added to 120 l of ice-cold acetonitrile containing internal standard. Concentrations of PF-02413873 in microsomal and buffer compartments were then assessed using LC-MS/MS.
Identification of Metabolites of PF-02413873 In Vitro. Experiments investigating routes of metabolism were conducted using the same liver microsome and hepatocyte preparations used to study metabolic turnover. Microsomal and hepatocyte incubations were conducted with PF-02413873 at an initial concentration of 1 M. Liver microsomal protein concentration was adjusted to 0.25 M of total P450, and hepatocyte incubations were performed at 0.5 ϫ 10 6 viable hepatocytes/ml. Incubations were conducted in a water bath at 37°C and, in the case of liver microsomes, were performed in the presence and absence of NADPH. At appropriate time-points, depending on previously measured half-lives, reactions were terminated by addition of five volumes of ice-cold acetonitrile. Terminated samples were centrifuged, and the supernatant was removed and evaporated to dryness under a stream of nitrogen. Dried samples were stored frozen until analysis.
Qualitative analysis to identify potential metabolites of PF-02413873 was conducted by HPLC-MS/MS. The HPLC aqueous mobile phase component of the binary gradient consisted of 0.1% v/v formic acid in water (mobile phase A), and the organic component consisted of 0.1% v/v formic acid in acetonitrile (mobile phase B). An Agilent 1100 binary pumping system (Agilent Technologies, Santa Clara, CA) was used to control the mobile phase gradient at 95% A for the first minute, changing linearly to 2% A at 8 min, followed by 1 min held at 2% A, then back to 95% A over 0.1 min, and held for 4 min. The gradient was delivered to a 2.1 ϫ 100 mm Sunfire C18 3 m analytical column (Phenomenex, Torrance, CA) via a CTC HTS Pal autosampler (LEAP Technologies, Carrboro, NC). The flow rate was set at 200 l/min and was introduced into the source of the mass spectrometer (Q-ToF Premier; Waters, Milford, MA) with no postcolumn split. The mass spectrometer was coupled to the HPLC via a Z-Spray interface (Micromass, Altrincham, UK) with a desolvation temperature of 350°C, a source temperature of 120°C, and a cone voltage of 25 V. Leucine-enkephalin was introduced into the ion source via a lock-spray inlet to provide a standard for accurate mass calibration. Positive ion mass spectrometry and MS/MS experiments were performed with the time-of-flight operated in V-mode, and data acquisitions were performed in centroid mode.
Animal Experimentation. All studies involving animals were conducted in compliance with United Kingdom national legislation and subject to local ethical review. At all stages, consideration was given to experimental refinement, reduction in animal use, and replacement with in vitro techniques.
PK in the Rat. Male Sprague-Dawley rats weighing approximately 250 g were used in the following studies. At least 48 h before compound administration, animals were surgically prepared by the placement of a cannula in the jugular vein. Throughout the study, animals were housed in stock boxes with access to food (RM1 rodent diet; Special Diet Service, Witham, Essex, UK) and water ad libitum. PF-02413873 was dissolved in 20% polyethylene glycol (PEG) in saline to a final concentration of 0.2 mg/ml. A total of 2 ml/kg was dosed either intravenously via the tail vein or orally by gavage to give a final dose of 0.4 mg/kg. Separate groups of rats (n ϭ 3) were used for each dose route. After dosing by either route, blood (approximately 175 l) was withdrawn via the jugular vein catheter at various times into heparin-coated tubes. The cannula was flushed with heparinized saline (10 units/ml) after each sample. Plasma was prepared by centrifugation at 2000g, and the samples were then stored at Ϫ20°C before analysis.
PK in the Dog. One female and one male dog weighing approximately 12 kg were used for the intravenous and oral studies conducted 1 week apart. Before the studies, the dogs were given food and water ad libitum. For both intravenous and oral administration, PF-02413873 was dissolved in dimethyl sulfoxide to a concentration of 10 mg/ml, then diluted with PEG 200 to 0.5 mg/ml, and finally with saline to a final concentration of 0.1 mg/ml in 1% dimethyl sulfoxide 20% PEG 200 in saline. Intravenous administration was by infusion via the saphenous vein of 2 ml/kg over 15 min to give a final dose of 0.2 mg/kg, and oral administration was via gavage at 2 ml/kg to give a final dose of 0.2 mg/kg.
On the day of dosing, the dogs were placed in slings and remained there for the first 6 h after dosing. This allowed blood samples (approximately 2 ml) to be collected from the saphenous vein by means of indwelling catheters. After this period, the dogs were returned to their pens and samples were obtained from the cephalic vein by venipuncture. After sampling, blood was centrifuged at 2000g and plasma was removed into separate Eppendorf tubes, which were stored at Ϫ20°C until analysis.
PF-02413873 Analysis in Rat and Dog Plasma Samples. PF-02413873 was extracted from 50-l aliquots of rat or dog plasma using a specific liquid-liquid extraction and HPLC method with mass spectrometric detection. Samples were prepared by the addition of 1 ml borate buffer, pH 10, containing 10 ng of internal standard PF-02327888, followed by 2 ml of tert-butylmethylester. Samples were vortex mixed, centrifuged at 2000g for 5 min, and 1.8 ml of the tert-butylmethylester layer was removed and blown to dryness under nitrogen at 40°C. The residues were reconstituted in 300 l of MF3, and 180 l was injected into an LC-MS/MS system for quantitation of analyte. In each assay, standard calibration lines were constructed using known amounts of PF-02413873 added into 50-l aliquots of blank plasma from the appropriate species.
Samples were analyzed using a Sciex API 4000 with turbo ion spray interface in positive ion multiple reaction monitoring mode with collision energy of 25 eV. The MRM transitions monitored were 360 to 280 for PF-02413873 and 358 to 278 for PF-02327888. Each sample was injected sequentially into the LC-MS/MS system with a CTC PAL autoinjector. The mobile phase (flow rate, 3 ml/min) was split 5:1 postcolumn using an Acurate flow splitter (Presearch Ltd., Hitchin, Hertfordshire, UK).
Clinical Study in Human Volunteers. The randomized, double-blind, third party open, placebo controlled dose-escalation study was conducted in healthy male subjects. The protocol was reviewed and approved by an independent ethics committee, and all subjects gave written informed consent. PF-02413873 was administered orally as a micronized suspension. Subjects were divided into two cohorts: Cohort 1 received 4 escalating doses (0.5, 5, 50, and 150 mg) with randomized placebo insertion in the fasted state plus one dose (150 mg) in the fed state; Cohort 2 received 3 doses (500, 1500, and 3000 mg) with randomized placebo insertion in the fed state. Subjects in the fed state received a standard high-fat, high-calorie breakfast. Serial blood samples for determination of plasma concentrations of PF-02413873 were collected for up to 120 h in Cohort 1 and up to 240 h in Cohort 2. Standard noncompartmental PK analysis was performed on plasma concentration data.
Analysis of Clinical PK Samples. Plasma samples were analyzed with a validated assay using PF-02339955 as an internal standard. PF-02413873 and internal standard were extracted from 100 l of human plasma using solidphase extraction. Thawed plasma samples were briefly mixed and centrifuged at 2000g for 10 min at room temperature. One hundred microliters of each sample was mixed with 100 l of methanol containing 200 ng/ml PF-02339955. After preconditioning of 15 mg of OMIX C18 tips (Quadra; Tomtec, Hamden, CA) with 2 ϫ 150 l of methanol followed by 150 l of water, the samples were loaded onto the C18 micropipette tips. The tips were washed with 2 ϫ 150 l of water, and the analytes eluted with 2 ϫ 75 l of methanol. Eluates were evaporated under nitrogen at 40°C, reconstituted with 200 l of MF5, and shaken for 10 min. Fifty microliters of each reconstituted sample was injected onto an LC-MS/MS system containing a 100 ϫ 4.6-mm Onyx Monolithic column (Phenomenex), and analyte was measured by MS/MS detection in an API 3000 triple-quadrupole mass spectrometer (AB Sciex Instruments) operating in positive ion MRM mode. The lower and upper limits of quantification of this assay were 1 and 500 ng/ml PF-02413873, respectively.
Prediction Methods. CL prediction from allometric SSS. PK in rat and dog were used to predict CL in human using the following equation (Hosea et al., 2009) : human CL u ϭ animal CL u ϫ ((human BW/animal BW) 0.75 ), where BW is body weight (kg), assumed to be 0.25 for rat, 12 for dog, and 70 for human, and CL u is the unbound plasma CL with units of ml/min. Then, plasma CL (CL p, ml ⅐ min Ϫ1 ⅐ kg Ϫ1 ) in human is given by the following: human CL p ϭ human CL u ϫ Fu/human BW.
CL prediction from in vitro metabolism. Using human liver microsomal turnover, prediction of in vivo intrinsic CL and, subsequently, hepatic CL was carried out using physiologically based scaling factor and the "well stirred" liver model as described in the literature (Obach et al., 1997; Ito and Houston, 2005) . It was assumed that human liver contains 45 mg/g microsomal protein and that there are 21 g liver/kg human body weight.
Dose prediction. Doses of PF-02413873 predicted to be required to achieve a given exposure were calculated from the relationship, assuming 100% absorption: Dose ϭ CL p /(1 Ϫ (CL b /Q)) ϫ AUC eff , where Q ϭ human hepatic blood flow; BPR ϭ blood/plasma ratio; CL b ϭ blood CL, calculated as CL p /BPR; AUC eff ϭ target AUC in plasma at steady state.
Prediction of plasma concentration versus time profiles in GastroPlus. The PBPK intravenous (disposition) and oral simulations were performed within the GastroPlus software using version 5.0. These models have been described in detail previously ). The choice of GastroPlus software offered the potential to incorporate biorelevant solubility and simulate PK profiles under fed and fasted conditions. The PBPK model was composed of several compartments corresponding to the different tissues of the body which are connected by the circulating blood system. Each compartment was defined by a tissue volume and a tissue blood flow rate that is specific for the species of interest. Each tissue was assumed to be perfusion rate limited. The liver was considered to be the only site of elimination. Tissue-to-plasma partition coefficients (K p s) and intrinsic CL (CL int ) predicted from preclinical data were required as input to this model. The K p values were predicted from physicochemical and in vitro inputs using methods described by Rodgers and Rowland (2006) . In brief, these equations account for partitioning of un-ionized drug into neutral lipids and neutral phospholipids, dissolution of drug in tissue water, and interactions with extracellular protein.
The Advanced Compartmental Absorption Transit (ACAT) model within GastroPlus was used to predict the rate and extent of oral absorption in human and preclinical species. The ACAT model has been described in detail previously (Agoram et al., 2001) and is based on the CAT model described by Yu and Amidon (1999) . The main input parameters for the FIG. 1. Proposed pathways of metabolism of PF-02413873 in microsomes and hepatocytes from rat, dog, and human liver. Labels next to arrows denote that metabolite was formed in microsomes from rat (RLM), dog (DLM), and human (HLM) and hepatocytes from rat (rHEP), dog (dHEP), or human (hHEP) liver. absorption prediction were as follows: solubility, permeability, particle size, LogD, and dose (Table 1) .
The following PBPK prediction strategy was followed as proposed by Jones et al. (2006a): 1. validation of intravenous disposition prediction in rat and dog 2. validation of oral absorption prediction in dog 3. simulation of disposition and absorption in human
Results
LogD 7.4 of PF-02413873. The geometric mean logD 7.4 of PF-02413873 was found to be 3.4 Ϯ 0.03 (S.E.M., n ϭ 6), consistent with its nature as a lipophilic, neutral (nonionizable) compound.
Validation of Analytical Methods. The PF-02413873 rat plasma assay displayed linearity of signal with concentration over a calibration range of 0.2 to 1000 ng/ml. Inaccuracy (6 replicate samples) was 1.4, 10.9, 2.8, and 10.7% at 1, 20, 100, and 200 ng/ml, respectively, and the imprecision at the same concentrations was 3.1, 8.7, 1.3, and 8.3%. The dog plasma assay displayed linearity of signal with concentration over a calibration range of 0.2 to 1000 ng/ml. Inaccuracy (6 replicate samples) was 1.7 and 3.7% at 5 and 500 ng/ml, respectively, and the imprecision at the same concentrations was 11.7 and 2.9%. The clinical assay was linear over a calibration range of 1 to 400 ng/ml and had an inaccuracy at 1, 3, 250, and 400 ng/ml of 7, 7, 2.8, and 0.5%, respectively. At the same concentrations, the imprecision was 6.1, 3.9, 2.6, and 6.4%.
Plasma Protein Binding and Blood/Plasma Ratio. In rat, dog, and human plasma, no concentration dependence of binding or differences between male and female were evident across a concentration range of 1.5 and 15 g/ml (rat), 1 and 10 g/ml (dog), and 0.1 and 1.0 g/ml (human) (data not shown). Therefore, a single value of Fu was used for each species based on the overall mean of the data across concentration and sexes. Thus, the Fu of PF-02413873 in rat, dog, and human plasma was 0.042, 0.035, and 0.031, respectively. The blood/plasma ratios of PF-02413873 in rat, dog, and human were 0.93, 0.82, and 0.61, respectively.
In Vitro Metabolism by Liver Microsomes and Recombinant
P450s and Microsomal Binding. In rat liver microsomes, the CL int,app of PF-02413873 was Ͼ500 l ⅐ min Ϫ1 ⅐ mg protein Ϫ1 (t 1/2] ϭ Ͻ2 min). In dog and human microsomes, CL int,app values were significantly lower than in rat, at 36 and 29 l ⅐ min Ϫ1 ⅐ mg protein Ϫ1 , respectively (t 1/2 ϭ 25 and 30 min, respectively). The unbound fraction of PF-02413873 in human liver microsomes was 0.78. In the recombinant P450 experiments, turnover of PF-02413873 was only detectable in the presence of rCYP3A4. The CL int,app value (1.27 l ⅐ min Ϫ1 ⅐ pmol P450 Ϫ1 ) calculated for rCYP3A4 was subsequently scaled to human liver, using the appropriate relative activity factor and intersystem extrapolation factor (Youdim et al., 2008) . The scaled rCYP3A4 CL int value was 25.9 l ⅐ min Ϫ1 ⅐ mg protein Ϫ1 . In Vitro Metabolism by Hepatocytes. In cryopreserved rat and dog hepatocytes, CL int,app of PF-02413873 was Ͼ500 and 20 l ⅐ min Ϫ1 ⅐ 10 6 cells Ϫ1 , respectively (t 1/2 ϭ Ͻ2 and 35 min, respectively). In human hepatocytes, the turnover of PF-02413873 (t 1/2 ϭ Ͼ120 min) was too low to allow an accurate measurement (Ͻ6 l ⅐ min Ϫ1 ⅐ 10 6 cells Ϫ1 ). Metabolite Profiles in In Vitro Systems. The main metabolites of PF-02413873 formed by liver microsomes and hepatocytes are shown in the scheme in Fig. 1 . After incubation with human liver microsomes, the major metabolite of PF-02413873 resulted from monooxidation of one of the methyl groups on the dimethylbenzonitrile moiety (M1). Further minor products of mono-oxidation of the methyl and/or cyclopropyl substituents of the pyrazole ring were also detected (M2 and M3), along with products of di-oxidation of both ring systems (M4 and M9). The mono-oxidized metabolite M3 was the only product formed after incubation of PF-02413873 in human hepatocytes. In rat and dog liver microsomes and hepatocytes, a similar range of mono-oxidized (M1, M2, M3) and di-oxidized products (M4 and M9) were found. The only product of phase 2 conjugation reactions that was found was a glucuronide in dog hepatocytes, a minor product that was most likely the result of conjugation to a hydroxylated metabolite (data not shown).
PK in Rat. The PK of PF-02413873 were determined after intravenous administration at a single dose of 0.4 mg/kg in male rats ( Fig. 2 ; PK parameters in Table 2 ). The mean elimination half-life was 1.1 h and CL p was 84 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 . After oral dosing, plasma concentrations of PF-02413873 were below the level of quantitation. Assuming that hepatic blood flow in the rat is 70 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 (Boxenbaum, 1980) , the lack of exposure after oral administration is consistent with the CL p observed after intravenous administration, i.e., CL p Ͼ hepatic blood flow. PK in Dog. The PK of PF-02413873 was determined after intravenous administration at a single dose of 0.2 mg/kg in dogs. The mean elimination half-life was 7.6 h, CL p was 3.8 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 , and V ss was 2.5 l/kg. The plasma concentrations after oral dosing of PF-02413873 are shown in Fig. 3 , and the PK parameters are shown in Table 3 . In contrast to rat, the plasma exposure and calculated PK parameters demonstrated high oral bioavailability of PF-02413873 in the dog and, furthermore, were consistent with complete absorption.
PK in Male Volunteers. The PK profiles of PF-02413873 in Cohort 1 (doses of 0.5-150 mg) are shown in Fig. 4 , the PK profiles in Cohort 2 are shown in Fig. 5 , and the derived PK parameters for both cohorts are shown in Table 4 . In subjects that were fasted, exposure increased slightly less than proportionally with doses between 5 and 150 mg. Exposure at 0.5 mg was too low in relation to the limit of quantitation to allow satisfactory calculation of all PK parameters. At 150 mg, dosing in fed subjects increased AUC inf by approximately 60% in comparison with fasted subjects, with a corresponding 76% increase in C max and delay in T max from 3 to 6 h. In fed subjects overall, exposure increased roughly in proportion to dose between 150 and 3000 mg. The terminal half-life of PF-02413873 over the dose range varied between 28 and 44 h, with no obvious pattern of variation that reflected dose or fed or fasted states. Oral CL ranged between approximately 4 and 7 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 , with the lower values reflecting higher AUC obtained per unit dose in the fed state.
Prediction of Human PK. The predictions of the Vd ss of PF-02413873 in rat, dog, and human using the tissue composition equations developed by Rodgers and Rowland (2006) are shown in Table 5 . These equations provided accurate estimates of Vd ss in rat and dog. When the K p values provided by this prediction method were combined with the observed CL as inputs, simulation of the intravenous concentration versus time profiles in rat and dog provided good approximations to the observed data. Therefore, the Rodgers and Rowland (2006) equations were used for PBPK simulation in human.
The ACAT model was able to accurately simulate the dog oral plasma concentration versus time profiles using the in vitro solubility, predicted K p values, and observed intravenous CLp as inputs to the model (Fig. 6) . Therefore, the ACAT model was used to simulate absorption in human. 
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Human CL p was predicted to be 13.5 and 2.6 ml ⅐ min Ϫ1 ⅐ kg
Ϫ1
when scaled from unbound CL p in rat and dog, respectively. When in vitro CL int determined in human liver microsomes (HLM) was used, the predicted human CL p was 1.0 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 . The prediction of blood CL from rat SSS (CL p /BPR ϭ 22 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 ) was close to hepatic blood flow in human (assumed to be 20 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 ). For this reason, CL from rat SSS was not used in subsequent simulations using GastroPlus.
Because intravenous administration was not undertaken in the clinical study, CL p predicted from preclinical data were compared with the range of oral CL (CL/F) determined in the clinical study. This demonstrated an overprediction by rat SSS. Predictions from dog SSS and from scaling of HLM turnover were more comparable with the measured human CL/F, and they were broadly consistent with characterization of PF-02413873 as a low CL molecule in human. Dog SSS provided the closest estimates of C max and AUC observed in the clinical study and predicted an oral CL of 5.5 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 , assuming complete absorption.
Separate preclinical pharmacological studies of PF-02413873 predicted that steady-state systemic exposure (AUC 0 -24 ) of approximately 6000 ng ⅐ h/ml would be required to elicit a pharmacological effect in human (data not shown). This information was combined with CL/F predictions to calculate approximate doses of 30 mg (HLM scaling) and 85 mg (dog SSS) that would be expected to be pharmacologically active and hence inform the range to be explored in early human studies (5-3000 mg).
GastroPlus simulations of the plasma concentration versus time profile of PF-02413873 after micronized suspension doses of 50, 150, and 500 mg in human alongside the actual measured plasma concentrations are shown in Fig. 7 . In general, the shapes of the profiles were predicted well using the Rodgers and Rowland (2006) K p values. However, plasma exposures of PF-02413873 (C max and AUC) were generally overpredicted using CL p predicted from HLM (up to 4-fold) and dog PK (up to 3-fold) (Table 6) , indicating a potential underprediction of CL.
At a dose of 150 mg, using CL predicted from HLM or dog SSS, biorelevant solubility (FaSSIF and FeSSIF), together with altered physiologies in the two feeding states, GastroPlus predicted increases in C max (approximately 2-fold) and AUC (approximately 1.2-fold) with food. These compared well with observed increases in C max and AUC in the clinical PK study of 1.8-and 1.6-fold, respectively. The model also predicted the slight reduction in dose-normalized exposure that was observed in the fasted state between 50 and 150 mg, consistent with saturation in absorption (Table 6 ). However, as doses increased to 500, 1500, and 3000 mg, the model predicted progressive reduction of dose-normalized exposure, while it remained broadly constant in the clinical study.
Discussion
A combination of preclinical in vitro metabolism and in vivo PK data was used to determine the likelihood that the PK of PF-02413873 in human would be suitable for its progression to clinical studies. In human in vitro systems, turnover of PF-02413873 was relatively low, so that scaling of HLM CL int to in vivo CL using the appropriate scaling factors and the well stirred liver model predicted low CL in human (Ͻ20% hepatic blood flow). The PK of PF-02413873 in rat and dog demonstrated that CL was high (greater than hepatic blood flow) in rat and low in dog (approximately 10% of hepatic blood flow). This result was in keeping with metabolic stability of PF-02413873 in liver microsomes and hepatocytes obtained from these species. These differences in PK and metabolic stability between rat and dog were reflected in predictions of human CL by SSS (Hosea et al., 2009 ) from the two species which are widely different; dog predicted low CL (approximately 20% hepatic blood flow) and rat predicted high CL (similar to human hepatic blood flow).
Metabolites of PF-02413873 formed in in vitro systems in all three species were products of oxidation. Although appearance in urine of unchanged PF-02413873 was not determined in the PK studies, its physicochemical characteristics (lipophilic neutral compound) make it unlikely that renal excretion is a significant CL pathway. Therefore, the major route of CL in vivo is likely to be via oxidative metabolism catalyzed by hepatic P450 enzymes. In the absence of quantifiable metabolite samples, rates of metabolite formation were not investi- (13) n, number of subjects assessed; AUC 0 -24 , area under the concentration-time curve from time 0 to 24 h postdose; AUC inf , area under plasma concentration vs. time profile from time 0 extrapolated to infinite time; C max , first incidence of maximal observed plasma concentration; T max , time at which C max was observed; t 1/2 , terminal half-life; Vz/F, apparent volume of distribution associated with the terminal phase; CL/F, apparent clearance after oral administration; NC, not calculated; CV, coefficient of variation.
a Geometric mean (CV%). b Median (range). c Arithmetic mean (CV%). dmd.aspetjournals.org gated. However, other studies that monitored disappearance of PF-02413873 showed that it was turned over by recombinant human P450s, with CYP3A4 displaying the highest turnover of those enzymes tested. When appropriate scaling factors were applied to the data based on enzyme abundance in human liver, a CL int value for CYP3A4 turnover of PF-02413873 was calculated that was similar to that measured in HLM. These data are consistent with CYP3A4 being the major P450 isoform involved in metabolism of PF-02413873 in human liver. However, further studies in vivo would be required to confirm the dominance of oxidative pathways in human and also to understand the potential pharmacokinetic interactions between PF-02413873 and other drugs known to be metabolized principally by CYP3A4 or that are inhibitors of this enzyme. Before constructing a model in GastroPlus for human PK simulation, the assumptions of the model were tested by reference to observed rat and dog PK profiles (Jones et al., 2006a; DeBuck et al., 2007) . This validation exercise showed that the Rodgers and Rowland (2006) equations provided the simulated profiles that most closely resembled the observed data. The intrinsic absorption of PF-02413873 was expected to be good, based on comparison of intravenous and oral PK determined in dog. The simulation of absorption in the dog using the ACAT model was found to provide a good approximation to the (Fig. 6C) . Because PF-02413873 possesses high lipophilicity (logD ϭ 3.4) and consequent low aqueous solubility (Ͻ10 g/ml in aqueous buffer), the formulation chosen for clinical use was a micronized suspension, intended to maximize particle surface area and, hence, dissolution rate. Thus, the absorption model used the particle size in the micronized formulation and solubility determined in biorelevant media (FaSSIF and FeSSIF). Estimates of CL from HLM and dog PK were then combined with the absorption and distribution model in GastroPlus, and simulations of PK profiles were performed with inputs of oral suspension doses in the planned FIH study single ascending dose range. Given the range of CL predictions, some uncertainty in the outcome of the FIH study existed. For instance, taking a Vd ss of 2.6 l/kg [Rodgers and Rowland (2006) prediction], effective t 1/2 estimates of approximately 8 and 24 h were calculated from CL predictions made from dog SSS and HLM scaling, respectively, whereas, conversely, prediction from rat SSS was consistent with little oral exposure due to a predicted large first pass. However, metabolic turnover rates exhibited by rat and dog liver microsomes were consistent with their respective CL determined in these species in vivo, providing some confidence that the low turnover in HLM would translate to low CL in human. Furthermore, similarity in microsomal CL int in dog and human suggest that the dog, rather than rat, may be the most appropriate species for SSS of human CL of PF-02413873. Therefore, confidence in acceptability of human PK was considered to outweigh the uncertainty, supporting progression of PF-02413873 to a FIH study.
The human PK of PF-02413873 determined after oral dosing in the Phase 1 study was characterized by low CL/F (4 -7 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 ) and terminal t 1/2 of 28 to 44 h, characteristics compatible with high oral bioavailability and a once-daily dose that would be desirable for therapeutic administration. Of the human CL prediction methods used, SSS from rat was not found to be a good guide because it greatly overpredicted observed CL. The predictions from dog SSS and scaling from HLM were much more consistent with the low oral CL exhibited by PF-02413873, in accordance with the observed metabolic turnover in liver microsomes (CL int in RLM Ͼ Ͼ DLM Ϸ HLM). Previous retrospective analysis of CL prediction methods suggested that if CL is principally via metabolism catalyzed by P450, HLM scaling was as predictive of oral CL as SSS based on data from rat, dog, and monkey (Hosea et al., 2009) . In the present study, metabolite profiling and scaling of CL int catalyzed by recombinant CYP3A4 were consistent with P450-mediated CL of PF-02413873. HLM scaling correctly predicted CL to be low in relation to hepatic blood flow, although the value was just below the observed CL range. Although turnover in HLM of lower concentrations of PF-02413873 could indicate potential underestimation of CL int at 1 M, P450 inhibition data (CYP3A4 IC 50 Ͼ10 M; data not shown) were consistent with a CYP3A4 K m for PF-02413873 of Ͼ1 M. Dog SSS provided the estimate of CL closest to that observed, and it was a better predictive model than rat in this instance. This corresponds with the retrospective analysis of Hosea et al., 2009 , who showed that dog SSS predicted oral CL within 2-fold of that observed in 52% of P450-cleared compounds, whereas HLM scaling achieved 30%. Our prospective use of preclinical data showed the following: 1) two of three prediction methods (HLM and dog SSS) predicted low human CL; 2) CL was likely to be principally via metabolism catalyzed by P450; and 3) in vitro CL int and in vivo CL correlated in dog and rat, i.e., low DLM CL int and high RLM CL int predicted low dog CL and high rat CL, implying P450-mediated CL, and that low HLM CL int is likely to predict low human CL.
Dose escalation in fasted subjects provided approximately doseproportional increases in AUC inf but less than dose-proportional increases in C max . Simulations in GastroPlus displayed trends toward overprediction of C max and underprediction of the terminal phase half-life, which could be explained by an underprediction of Vd ss . This theory was confirmed by increasing the muscle K p (largest tissue mass), resulting in a lower predicted C max and a better prediction of the terminal phase (data not shown).
Provision of a standard high-fat, high-calorie food before dose administration led to an increase in exposure over fasted subjects, as demonstrated by an increase in AUC inf and C max at a dose of 150 mg. Remarkably, exposure was also found to increase largely in proportion to dose in fed subjects from 150 to 3000 mg. This suggests that absorption was enhanced in fed subjects, presumably as a result of changes in increased secretion of bile acids with consequent higher dissolution rate. The increased exposure with food was captured at doses of 150 and 500 mg using the ACAT model, which accounts for the increased stomach transit time, the change in stomach pH, and the biorelevant solubility data that incorporates solubility differences in the presence and absence of bile salts. Although the model was unable to fully account for the approximately dose-linear exposure increase from 500 to 3000 mg under fed conditions, it was able to predict that dosing PF-02413873 with food would increase exposure at the higher end of its dose range and permit extensive testing of pharmacologically relevant exposures. Other studies have demonstrated the utility of PBPK methodology and GastroPlus, incorporating biorelevant solubility, for simulating food effects of lipophilic compounds (Jones et al., 2006b; Parrott et al., 2009) , although these examples were generally weak bases. In this program, as the modeling provided evidence for a higher exposure with food, the plan for the subsequent repeat dose part of the clinical study incorporated fed subjects to optimize exposure for a given dose. Furthermore, the PBPK model in GastroPlus allowed simulation of repeat dose scenarios of PF-02413873, targeting pharmacologically relevant exposures that were also within acceptable limits established in separate preclinical safety studies (e.g., 150 mg per day under fed conditions).
In conclusion, the nonsteroidal PR antagonist PF-02413873 possessed low oral CL in human with a PK profile consistent with a once daily dosing schedule. Further studies are required in appropriate subjects to confirm the duration of desired PR pharmacological effects that would lead to amelioration of symptoms in gynecological diseases. The PK characteristics, including an increase in exposure in fed subjects, were predicted well using an ACAT model in GastroPlus and low CL prediction from HLM scaling and dog SSS. This represents a case study that highlights the prospective use of preclinical data combined with PBPK modeling techniques to provide predictions that guide decision making and design of early clinical trials of novel chemical agents.
